Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pamrevlumab - FibroGen

Drug Profile

Pamrevlumab - FibroGen

Alternative Names: Anti-CTGF antibody; FG-3019

Latest Information Update: 07 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FibroGen
  • Class Antifibrotics; Antineoplastics; Cardiovascular therapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Pancreatic cancer; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic pulmonary fibrosis; Pancreatic cancer
  • Phase II Duchenne muscular dystrophy
  • Discontinued Diabetic cardiomyopathy; Diabetic nephropathies; Diabetic neuropathies; Glioblastoma; Glomerulonephritis; Hepatic fibrosis

Most Recent Events

  • 30 Sep 2019 Safety and efficacy data from the phase II PRAISE study in Idiopathic pulmonary fibrosis released by FibroGen
  • 30 Sep 2019 FibroGen plans an open-label, extension study for Idiopathic pulmonary fibrosis
  • 22 Jul 2019 FibroGen plans a phase III trial in Idiopathic pulmonary fibrosis (In adults, In the elderly) in June 2019 (IV) (NCT03955146)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top